Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Patent metadata

Field	Value
Publication number	US-11234960-B2
Application number	US-201514644912-A
Country	US
Kind code	B2
Filing date	Mar 11, 2015
Priority date	Dec 23, 2010
Publication date	Feb 1, 2022
Grant date	Feb 1, 2022

Abstract

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

First claim

We claim:

1. A method of treating a neurodegenerative disease, comprising:
administering to a subject in need thereof a therapeutically effective amount of urolithin A, thereby treating the neurodegenerative disease; wherein the effective amount of urolithin A is about 140 mg to about 8,400 mg; and the neurodegenerative disease is selected from the group consisting of AIDS dementia complex, Alzheimer's disease, dementia with Lewy bodies, Huntington's disease, and Parkinson's disease.

2. The method of claim 1 , wherein the urolithin A is administered orally.

3. The method of claim 1 , wherein the urolithin A is administered parenterally.

4. The method of claim 1 , wherein the urolithin A is administered at least weekly.

5. The method of claim 1 , wherein the urolithin A is administered at least daily.

6. The method of claim 1 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Huntington's disease, and Parkinson's disease.

7. The method of claim 1 , wherein the neurodegenerative disease is Alzheimer's disease.

8. The method of claim 1 , wherein the neurodegenerative disease is Parkinson's disease.

9. The method of claim 1 , wherein the neurodegenerative disease is Huntington's disease.

10. The method of claim 1 , wherein the subject is a human.

11. The method of claim 6 , wherein the subject is a human.

12. The method of claim 7 , wherein the subject is a human.

13. The method of claim 8 , wherein the subject is a human.

14. The method of claim 9 , wherein the subject is a human.

15. The method of claim 1 , wherein the urolithin A is administered in the form of a pharmaceutical.

16. The method of claim 1 , wherein the urolithin A is administered in the form of a medical food.

17. The method of claim 1 , wherein the urolithin A is administered in the form of a functional food.

18. The method of claim 1 , wherein the urolithin A is administered in the form of a food additive.

19. The method of claim 1 , wherein the urolithin A is administered in the form of a dietary supplement.

20. The method of claim 1 , wherein the urolithin A is administered in the form of a food product.

21. The method of claim 1 , wherein the urolithin A is administered in the form of a nutritional supplement.

Assignees

• Amazentis Sa

Inventors

• Rinsch Christopher L
• Blanco-Bose William
• Schneider Bernard
• Thomas Charles
• Sandi Carmen
• Auwerx Johan
• Andreux Penelope
• Houtkooper Richardus
• Pirinen Eija
• Mouchiroud Laurent
• Genoux David

Classifications

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A23V2200/326

  having effect on cardiovascular health · CPC title

• A23L33/105 Primary

  Plant extracts, their artificial duplicates or their derivatives · CPC title

• A61K31/352

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title